ClinicalTrials.gg
CompletedNCT00339079Updated Apr 25, 2017Results posted

Treatment of Hypochondriasis With CBT and/or SSRI

A Phase 1/2 interventional study of Fluoxetine and Cognitive Behavioral Therapy (CBT) in Hypochondriasis, sponsored by Brigham and Women's Hospital. Completed at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-04-25.

Sponsored by Brigham and Women's Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis.

Read the detailed description

Hypochondriasis is one of the most difficult psychiatric disorders to treat. People with hypochondriasis believe that real or imagined physical symptoms are signs of serious illnesses, despite medical reassurance and other evidence to the contrary. Symptoms of the disorder include a preoccupation with fear of an illness; a persistent fear of having a serious illness, despite medical reassurance; and misinterpretation of symptoms. Some individuals with hypochondriasis recognize that their fear of having a serious illness may be excessive, unreasonable, or unfounded. Episodes of hypochondriasis usually last from months to years, with equally long periods of remission. Cognitive behavioral therapy (CBT) and the antidepressant drug fluoxetine (FLX) have both been shown to be effective treatments for hypochondriasis. However, the relative efficacy of a combined approach has yet to be determined. This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis.

Participants in this double-blind study will first report to the study site for two sessions to determine eligibility for participation. Eligible individuals will then be randomly assigned to receive one of the following four treatments for 12 weeks: CBT only; FLX only; CBT plus FLX; or a placebo pill. All participants receiving medication will also receive supportive therapy. Treatment response will be assessed at Week 12, and participants who have shown improvement will continue in the study for an additional 12 weeks. Participants who have not responded to treatment will be removed from the study and will receive open treatment. Participants assigned to receive medication or placebo will take medication once daily for the full 24 weeks. Participants assigned to CBT only or CBT plus FLX will receive CBT weekly for the first 8 weeks, then biweekly until Week 12, and then monthly until week 24. Outcomes will be assessed at study visits at Weeks 6, 12, 24, and 48, and over the phone at Week 36.

02

Conditions studied

  • Hypochondriasis
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.

Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for hypochondriasis; ascertained by Structured Diagnosis for Hypochondriasis module of SCID-I, and meets a hypochondriasis severity rating of at least "moderate".
  • Drug free for 6 weeks of all psychoactive or medications (seven weeks for fluoxetine).
  • Approval from treating physician if concomitant psychoactive medications need to be withdrawn prior to study participation.
  • English fluency and literacy.

Exclusion criteria

Exclusion Criteria

  • Pregnant or nursing mothers and women of who are not taking adequate precautions.
  • Any of the following Axis I mental disorders: chronic pain syndrome, schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder, alcohol abuse or dependence disorder (current or within the last six months), or substance abuse or dependence disorder (current or within the last twelve months). Patients with other comorbid psychiatric disorders are eligible based on the following three criteria: hypochondriasis must be the predominant presenting disorder; patient can not have a major co-morbid psychiatric disorder rated as "severe" on the Clinical Global Impressions Scale (CGI Scale); and patients can not have a co-morbid psychiatric disorder that causes significant functional impairment (significant functional impairment will be defined as an impairment that interferes in a marked way with expected role functioning, vocational and/or interpersonal).
  • Suicidality within the last 6 months as established by a score of 9 or more on the suicidality module of the MINI Plus.
  • Symptom-contingent pending litigation, disability compensation, or workers' compensation proceedings
  • Major medical illness expected to worsen significantly, lead to hospitalization, or likely to prove fatal in the next six months, established with the Cumulative Illness Rating Scale (CIRS); Stable, chronic medical illness is not an exclusion criterion
  • Not able to withdraw from concomitant psychoactive medications or currently taking necessary other medication that might interact adversely with fluoxetine:
  • abnormalities in , laboratory tests (including thyroid function) or physical examination. "Clinically important" abnormalities are those that signify a treatment intervention is needed or a medical abnormality has not been sufficiently addressed. Patients with medical problems that are stable and chronic are eligible, but patients with medical problems that are unstable, acute, or inadequately evaluated will be excluded. A current electrocardiogram is required for all patients with symptoms suggestive of cardiac disease, including chest pain, dyspnea, palpitations, or lightheadedness; if no current electrocardiogram exists, the study will obtain one.
  • History of severe side effects associated with fluoxetine or noncompliance with prior CBT for hypochondriasis
  • Previous adequate trial of either fluoxetine (eight weeks of which two weeks were at a minimum dose of 60 mg/day) or CBT for hypochondriasis (at least four sessions specifically targeting hypochondriacal symptoms) will be excluded, regardless of prior response. Inability to ambulate or mobility restrictions that prohibit frequent travel to the hospital for treatment and evaluation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    Cognitive Behavioral Therapy (CBT)

    Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.

    Behavioral: Cognitive Behavioral Therapy (CBT)

  • Placebo comparator
    Placebo

    Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.

    Other: Supportive Therapy · Drug: Placebo

  • Experimental
    Fluoxetine

    Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.

    Drug: Fluoxetine · Other: Supportive Therapy

  • Experimental
    Combined CBT and Fluoxetine

    Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.

    Drug: Fluoxetine · Behavioral: Cognitive Behavioral Therapy (CBT)

Interventions

  • Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.

    Also known as: Prozac, Prodep, Sarafem, Lovan, Symbyax, Fluctin

  • BehavioralCognitive Behavioral Therapy (CBT)

    CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.

  • OtherSupportive Therapy

    The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.

  • DrugPlacebo

    Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.

06

What researchers measure

Primary outcomes

  1. 25% Improvement on Both Whiteley Index and H-YBOCS-M

    Whitley index is a self-report measure of hypochondriasis H-YBOCS-M is an independent evaluator structured assessment of hypochondriasis

    Time frame: Measured at Week 24

Secondary outcomes

  1. Columbia Heightened Illness Concern - Obsessive-Compulsive Scale

    The Columbia Heightened Illness Concern - Obsessive-Compulsive Scale was the name for an earlier version of the H-YBOCS-M. The H-YBOCS-M is an expanded version and has additional items not included in the Columbia Heightened Illness Concern OCS. We did not administer the CHIC-OCS to patients in this study.

    Time frame: Not measured

07

Results

Posted Mar 3, 2017
Limitations and caveats
1) Limited generalizability since we studied volunteers not medical patients. 2) Sampling bias possible as many subjects sought CBT and were unwilling to take chance of being randomized to medication. 3) Relatively high rates of attrition.

Participant flow

The recruitment period was from October 2003 to July 2008. Participants were recruited via advertisements to the general public (e.g., newspaper ads).

Participant flow — Overall Study
MilestoneCognitive Behavioral Therapy (CBT)PlaceboFluoxetineCombined CBT and Fluoxetine
Started53444553
Completed20212729
Not completed33231824

Outcome measures

Primary25% Improvement on Both Whiteley Index and H-YBOCS-M

Whitley index is a self-report measure of hypochondriasis H-YBOCS-M is an independent evaluator structured assessment of hypochondriasis

Time frame:
Measured at Week 24
Reported as:
Count of participants · Participants
25% Improvement on Both Whiteley Index and H-YBOCS-M
ParticipantsCognitive Behavioral Therapy (CBT)PlaceboFluoxetineCombined CBT and Fluoxetine
25% Improvement on Both Whiteley Index and H-YBOCS-M21132025
SecondaryColumbia Heightened Illness Concern - Obsessive-Compulsive Scale

The Columbia Heightened Illness Concern - Obsessive-Compulsive Scale was the name for an earlier version of the H-YBOCS-M. The H-YBOCS-M is an expanded version and has additional items not included in the Columbia Heightened Illness Concern OCS. We did not administer the CHIC-OCS to patients in this study.

Time frame:
Not measured

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event data were continually collected and reported annually when the continuing review was submitted to the human research committee.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitive Behavioral Therapy (CBT)—0/53 (0%)0/53 (0%)
Placebo—0/44 (0%)1/44 (2.3%)
Fluoxetine—0/45 (0%)0/45 (0%)
Combined CBT and Fluoxetine—0/53 (0%)0/53 (0%)
Most frequent other events
Most frequent other events
EventCognitive Behavioral Therapy (CBT)PlaceboFluoxetineCombined CBT and Fluoxetine
Medication SwitchPsychiatric disorders0/531/440/450/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cognitive Behavioral Therapy (CBT)PlaceboFluoxetineCombined CBT and FluoxetineTotal
Mean39.2 ± 13.736.4 ± 12.943.1 ± 15.940.0 ± 14.339.7 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Cognitive Behavioral Therapy (CBT)PlaceboFluoxetineCombined CBT and FluoxetineTotal
Female2415252185
Male29292032110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitive Behavioral Therapy (CBT)PlaceboFluoxetineCombined CBT and FluoxetineTotal
Hispanic or Latino539623
Not Hispanic or Latino48413647172
Unknown or Not Reported00000
08

Study locations

2 sites
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Columbia Medical Center, New York Psychiatric Institute
    New York City, New York 10032, United States
09

References and documents

Publications

  • Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA. 2004 Mar 24;291(12):1464-70. doi: 10.1001/jama.291.12.1464. PubMed 15039413 ↗
  • Barsky AJ, Wyshak G. Hypochondriasis and somatosensory amplification. Br J Psychiatry. 1990 Sep;157:404-9. doi: 10.1192/bjp.157.3.404. PubMed 2245272 ↗
  • Barsky AJ. A 37-year-old man with multiple somatic complaints. JAMA. 1997 Aug 27;278(8):673-9. No abstract available. PubMed 9272901 ↗
  • Fallon BA, Ahern DK, Pavlicova M, Slavov I, Skritskya N, Barsky AJ. A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis. Am J Psychiatry. 2017 Aug 1;174(8):756-764. doi: 10.1176/appi.ajp.2017.16020189. Epub 2017 Jun 29. PubMed 28659038 ↗
  • Scarella TM, Laferton JA, Ahern DK, Fallon BA, Barsky A. The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders. Psychosomatics. 2016 Mar-Apr;57(2):200-7. doi: 10.1016/j.psym.2015.10.006. Epub 2015 Oct 23. PubMed 26785798 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of May 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2006
First posted
Jun 20, 2006
Start
Jun 2006
Primary completionActual
May 2011
CompletionActual
Dec 2011
Results first posted
Mar 3, 2017
Last update
Apr 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00339079
Responsible party
Arthur Joseph Barsky III,M.D. (Vice Chair for Psychiatric Research, Brigham and Women's Hospital) — Principal investigator
First posted
Jun 20, 2006
Start date
Jun 2006
Primary completion
May 2011
Completion
Dec 2011
Results posted
Mar 3, 2017
Last update
Apr 25, 2017

Study contacts

Arthur J. Barsky, MD
principal investigator · Brigham and Women's Hospital and Harvard Medical School
Brian Fallon, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluoxetine

Start the discussion